Clinical Trial Update: A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer [Phase 1]

View source ↗

Summary

This Phase 1 trial update reports results for a NY-ESO-1 vaccine with the GLA-SE adjuvant in patients with unresectable or metastatic cancer, including melanoma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Melanoma
• Non-small Cell Lung Cancer
• Ovarian Cancer
• Sarcoma

Drugs mentioned

• GLA-SE (glucopyranosyl lipid adjuvant in stable emulsion)
• NY-ESO-1 (New York esophageal squamous cell carcinoma antigen-1)

Snippet

Sponsor: Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Melanoma, Ovarian Cancer | Phase 1 | Status: COMPLETED